Antibodies to CD44 and integrin alpha(4), but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment

Citation
S. Brocke et al., Antibodies to CD44 and integrin alpha(4), but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment, P NAS US, 96(12), 1999, pp. 6896-6901
Citations number
70
Categorie Soggetti
Multidisciplinary
Journal title
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
ISSN journal
00278424 → ACNP
Volume
96
Issue
12
Year of publication
1999
Pages
6896 - 6901
Database
ISI
SICI code
0027-8424(19990608)96:12<6896:ATCAIA>2.0.ZU;2-H
Abstract
The role of various adhesion molecules in lymphocyte homing to the brain an d in inflammatory autoimmune disease of the central nervous system (CNS) wa s examined in mice, Activated T cell lines and clones expressed CD44 and in tegrin alpha(4), but not L-selectin, and entered the CNS independent of the ir antigen specificity. mAbs directed against CD44 and integrin alpha(4) pr evented the transfer of experimental autoimmune encephalomyelitis (EAE) by myelin basic protein-specific T cells. T cells preincubated with anti-CD44 or antiintegrin alpha(4) were blocked only partially from entering the brai n parenchyma, However, both antibodies efficiently prevented CNS inflammati on and clinical expression of EAE when injected in vivo. This effect lasted as long as antibodies were administered. Antibodies specific for L-selecti n had no effect on homing of encephalitogenic T cells to the brain or devel opment of EAE, Antiintegrin alpha(4) and anti-CD44 did not impair the activ ation and function of encephalitogenic T cells in vitro and did not deplete integrin alpha(4)- or CD44-positive cells in vivo. These data suggest that , in the absence of leukocyte recruitment, the entry of a reduced number of activated myelin basic protein-reactive T cells in the CNS is not sufficie nt for the development and expression of EAE. We propose that antibodies to integrin alpha(4) and CD44 prevent clinical disease by partially targeting the primary influx of encephalitogenic T cells and by preventing the secon dary influx of leukocytes to lesions initiated by the transferred T cells.